Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
Authors
Keywords
-
Journal
Journal of the American Heart Association
Volume 10, Issue 2, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-01-07
DOI
10.1161/jaha.120.018304
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis
- (2020) Safi U. Khan et al. CIRCULATION
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
- (2019) Renato D. Lopes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
- (2019) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention
- (2019) Joo-Yong Hahn et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
- (2019) Hirotoshi Watanabe et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial
- (2019) Stephan Windecker et al. CIRCULATION
- Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
- (2019) Pascal Vranckx et al. LANCET
- Ticagrelor with or without Aspirin in High-Risk Patients after PCI
- (2019) Roxana Mehran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
- (2018) Davide Capodanno et al. Nature Reviews Cardiology
- Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
- (2018) Pascal Vranckx et al. LANCET
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
- (2017) Marco Valgimigli et al. EUROPEAN HEART JOURNAL
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
- (2017) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
- (2016) C. Michael Gibson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plea for routinely presenting prediction intervals in meta-analysis
- (2016) Joanna IntHout et al. BMJ Open
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
- (2013) Willem JM Dewilde et al. LANCET
- The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews
- (2013) Rebecca M. Turner et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now